Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Boehringer Ingelheim Clinical Study Identification Number or study title by entering text and clicking search.

 

350 found

Click the study title to find more information about the study.

BI-1248.7
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Medicine: BI 54903, Condition: Asthma, Phase: 2, Clinical Study ID: 1248.7, Sponsor: Boehringer Ingelheim
BI-1248.5
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Medicine: BI 54903, Condition: Asthma, Phase: 2, Clinical Study ID: 1248.5, Sponsor: Boehringer Ingelheim
BI-1248.6
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Medicine: BI 54903, Condition: Asthma, Phase: 2, Clinical Study ID: 1248.6, Sponsor: Boehringer Ingelheim
BI-1047.16
Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy

Medicine: budesonide, Condition: Asthma, Phase: 3, Clinical Study ID: 1047.16, Sponsor: Boehringer Ingelheim
BI-1200.123
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Medicine: afatinib, Condition: Lung Neoplasms, Phase: 2, Clinical Study ID: 1200.123, Sponsor: Boehringer Ingelheim
BI-1200.70
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Medicine: afatinib, Condition: Carcinoma, Non-Small-Cell Lung, Phase: 1, Clinical Study ID: 1200.70, Sponsor: Boehringer Ingelheim
BI-1200.26
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification

Medicine: afatinib , Condition: Neoplasms, Phase: 2 , Clinical Study ID: 1200.26, Sponsor: Boehringer Ingelheim
BI-1200.24
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Medicine: afatinib , Condition: Neoplasms, Phase: 2 , Clinical Study ID: 1200.24, Sponsor: Boehringer Ingelheim
BI-1200.23
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Medicine: afatinib , Condition: Carcinoma, Non-Small-Cell Lung, Phase: 3, Clinical Study ID: 1200.23, Sponsor: Boehringer Ingelheim
BI-1200.10
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer

Medicine: afatinib , Condition: Breast Neoplasms, Phase: 2, Clinical Study ID: 1200.10, Sponsor: Boehringer Ingelheim
First Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  ... Next Last